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1. Introduction
Surgery still has its place in the treatment of inflammatory bowel diseases (IBD) but it is re‐
served generally to cases in which medical treatment is unsuccessful in relieving symptoms,
preventing disease progression and complications. As the medical treatment has added new
drugs (especially newly targeted therapy) and surgical advance in technology has gain in
more complex procedures with less morbidity and mortality and minimal invasivity there is
a need for periodic update.
2. Perioperative care of patients with IBD
Good perioperative care always ensures better surgical results. Patients undergoing surgery
for IBD must be prepared psychologically and medically.
Psychological preparation should start by explaining the patient the need for surgery. In this
approach the surgeon must be aided by the gastroenterologist that has managed the patient
for a long time in most of the cases. After acceptance of surgery, the patient must be ex‐
plained the objectives, the advantages and disadvantages of each surgical intervention and
the decision must be taken in common. People that will be submitted to stomas should also
get a consultation from stomatherapist.
Medical preparation of the patients includes correction of hemoglobin, volemia, electrolytes
and acid-base levels, coagulopathy, liver function. Total parenteral nutrition may be neces‐
sary in patients with nutritional deficits. Coexisting diseases should also be addressed. Any
corticosteroid and immunosuppressive therapy should be discontinued before surgery, but
corticosteroids need to be tapered immediately after surgery.
© 2012 Surlin et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2.1. Prevention of infection
Adequate antibiotic prophylaxis or antibiotic therapy should be given, especially in cases
with prolonged corticosteroid or infliximab therapy. Anyway, antibiotic prophylaxis pre
and intraoperative is mandatory in colon surgery, but we think that may be continued sev‐
eral days after surgery especially in patient treated by corticosteroids and immunosupres‐
sive and immunomodulator therapy because of higher risk of infection on a reduced
immune host defense.
The mechanical bowel preparation in elective cases is no longer mandatory in colon surgery
and is contraindicated in patients with an acute abdomen or obstruction [1]
2.2. Prophylaxis for venous thrombosis
Patients with IBD are at increased risk for thromboembolic venous and arterial complica‐
tions [2, 3]. Thus, intermittent pneumatic compression and/or low dose heparin should be
used prophylactically.
3. Indications for surgery in ulceative colitis (UC)
Approximately 30–40% of patients with ulcerative colitis will require surgical treatment.
Indications for surgery are:
• intractable chronic disease,
• lack of response to high-dose corticosteroid therapy
• recurrence of symptoms upon stop of corticosteroid therapy,
• disease progression under maximal medical therapy,
• significant treatment-related complications such as severe steroid or infliximab side ef‐
fects,
• dysplasia or cancer in patients with long-standing colitis during endoscopic surveillance,
• colonic strictures,
• acute exacerbation of the disease not responsive to rescue therapy such as intravenous
steroids, cyclosporine, or infliximab,
• acute complications: hemorrhage, toxic megacolon, perforation, fulminant colitis,
• extracolonic manifestations.
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3.1. Elective procedures
The development of restorative procedures such as the ileal pouch anal-canal anastomosis
has made surgery a more attractive option in patients in whom medical therapy has been
unsuccessful or undesirable.
3.2. Refractory colitis
The treatment of choice for acute severe steroid refractory ulcerative colitis is controversial
[4]. Gastroenterologists sustain infliximab [5], while surgeons plead for colectomy [6].
3.3. Intractable chronic disease
The most common indication for elective surgery is disease activity that has been intractable
to medical therapy. However, "intractable" is kind of blurry. Some authors have suggested
that disease should be considered intractable when it or its treatment is associated with se‐
vere and persistent impairment in the quality of life [7]. However, these parameters are dif‐
ficult to measure and are variable among individual patients.
3.4. Refractory Acute Severe Ulcerative Colitis (RASUC)
Refractory acute severe ulcerative colitis (RASUC), is defined by greater than six bloody
stools per day and one of the following: heart rate more that 90 beat/min, erythrocyte sedi‐
mentation rate more than 30mm/h, temperature more than 37.8°C, and hemoglobin less than
10.5 g/dl. The appropriate time to initiate surgical intervention during the treatment of RA‐
SUC has been a topic of investigation, because patients are usually severely malnourished,
immunocompromised, and weakened by side-effects of immunomodulating drugs. [8].
3.5. Emergency surgery
Advances in medical therapy (including use of infliximab) have reduced the need for emer‐
gency surgery due to catastrophic complications such as massive hemorrhage, perforation,
fulminant colitis, and acute colonic obstruction [9].
A longer duration of in-hospital ineffective medical therapy (8 versus 5 days) that delays
surgical therapy in patients with acute severe ulcerative colitis is associated with an in‐
creased risk of postoperative complications [10].
Biologic agents were introduced with the intent to help avoid operative intervention in pa‐
tients with moderately to severely active IBD who have demonstrated an inadequate re‐
sponse to conventional therapies. Ananthakrishnan et al. analyzing a large number of cases
hospitalized for IBD found that the use of biologic agents decreases the incidence of emer‐
gency surgery in patients with mild disease, but not in those with severe forms. [11]
For Ousslan et al, failure to respond to infliximab determined the decision for colectomy in
19% of the patients. Predicting factors for colectomy were C-reactive protein > 10mg/l before
treatment with infliximab, hemoglobin less than 9.4 g/dl, episodic use of infliximab, and pre‐
vious treatment with cyclosporin. [12]
An Update to Surgical Management of Inflammatory Bowel Diseases
http://dx.doi.org/10.5772/53057
3
In the study of Gustavsson et al, with 3-year follow-up, infliximab significantly reduced the
need for surgery at 3 month compared to placebo (29% vs 67%), for patients with corticoste‐
roid refractory UC. At 3 years, 50% of patients in the infliximab group and 76% of patients
in placebo group needed colectomy. [13]
In a spanish multicenter experience, patients in whom corticosteroids and ciclosporin failed
to control the disease, were submitted to infliximab. A 40 years patient, operated because of
infliximab failure died after surgery from nosocomial pneumonia. Authors stated that sal‐
vage therapy with infliximab after failed corticosteroids and ciclosporin may be associated
with risk for morbidity and mortality and therefore should be used in selected patients. [14]
Adalimumab emerged as an indication in the cases in which there is partial or no response
to infliximab. In a study from Taxonera et al at 48 weeks of follow-up only 20% of the pa‐
tients needed surgery. Therefore, application of this new therapy may diminish the indica‐
tions for surgery in the group of patient non-responders to infliximab therapy.
3.6. Suspicion of cancer
The risk of malignancy is directly proportional to the duration of disease. The risk during
the first decade of disease is low, but increases substantially after that. After 30 years of dis‐
ease the risk is about 50 %. [8] Patients with more than 10 years of disease should undergo a
colonoscopy each year. Most of the gastroenterologists consider discovery of moderate to se‐
vere dysplasia an indication for surgery.
3.7. Extraintestinal manifestations
Surgical indication is seldom for extracolonic manifestations of IBD. Benefits from surgery
will be in the rare cases of massive hemolytic anemia unresponsive to treatment. In those
cases splenectomy should be associated to colectomy [7]. Another extracolonic indication for
colectomy is thromboembolic complications. Erythema nodosum and arthralgia of the small
and large joints appear to benefit the most from proctocolectomy [15]. In cases of pyoderma
gangrenosum, ankylosing spondylitis and arthritis, sclerosing cholangitis surgery may not
be so profitable.
Surgical options for ulcerative colitis are:
• Proctocolectomy with permanent ileostomy (Brooke ileostomy)
• Proctocolectomy with continent ileostomy (Kock pouch)
• Abdominal colectomy with ileorectal anastomosis
• Colectomy, mucosal proctectomy, and ileal pouch-anal canal anastomosis (IPAA)
• Colectomy and stapled ileal pouch distal rectal anastomosis (IPDRA)
3.8. Elective procedures
• Curative procedure - Proctocolectomy with permanent ileostomy.
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• Avoiding of ileostomy - IPAA. Patients under infliximab - three stages IPAA
In the elective surgical population, the standard operation performed is a total proctocolec‐
tomy with ileal pouch anal anastomosis. Described by Parks and Nichols in 1978, the proce‐
dure involves excision of the abdominal colon, pelvic dissection to remove the rectum,
creation of an ileal reservoir, and anastomosis of the pouch to the anus. A variety of pouch
designs can be used. The most commonlyof thrm is the J-pouch. Preference for the J-pouch
lies in its limited use of bowel, reliable emptying, and ease of construction. [8]
Mortality is low - 0.2–0.4%; however, the risk of pelvic sepsis can be as high as 23% from
leaks from the ileoanal anastomosis. To prevent this complication, the operation could be
performed in multiple stage (two or three), to allow anastomoses to heal without important
consequences [16,17].
3.9. In emergency situations
Toxic megacolon – the procedure of choice is open colectomy with ileostomy and closure of
the rectum or distal colostomy. The rectum may be resected afterwards with ileal pouch-
anal anastomosis. IPAA from the beginning should not be performed because of risk of
complications.
Hemmorhage – Proctocolectomy, suture of a bleeding ulcer or Hartmann-type colectomy
leaving a small stump of distal rectum.
3.10. Other options for restorative proctocolectomy
Ileal pouch distal rectum anastomosis (IPDRA) – anastomosis between ileal pouch and dis‐
tal rectum – easier to perform, better anal sensation and continence especially at night.
Main disadvantage – leaving rectal mucosa behind, that should be avoided in patients with
cancer or severe dysplasia in colorectal mucosa, severe extraintestinal manifestations.
Advantage – older patients, lack of adequate mobilisation for tension-free anastomosis –
ileorectal anastomosis (IRA)
Indications
• Patients not suitable for IPAA
• Refusal of ileostomy
• Medical conditions in which a stoma is relatively contraindicated (eg, portal hypertension
or ascites),
• Women of childbearing age because of the risk of infertility,
• Patients in whom Crohn's disease cannot be excluded,
• Patients with colitis complicated by advanced colonic malignancy,
Functional results after IRA
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A retrospective analysis of the functional results after IRA for ulcerative colitis or indetermi‐
nant colitis in 86 patients found that the rectum was eventually resected in 17% of cases, rec‐
tal dysplasia occurred in 17%, rectal cancer 8% and refractory proctitis 28%. The cumulative
probability of developing rectal dysplasia at 5, 10, 15, and 20 years was 7, 9, 20, and 25 per‐
cent, respectively. The cumulative probability of developing rectal cancer at 5, 10, 15, and 20
years was 0, 2, 5, and 14 percent, respectively. The cumulative probability of having a func‐
tioning IRA at 10 and 20 years was 74 and 46 percent, respectively. [18]
Satisfactory rectal function varies greatly depending upon the selections of patients and
length of follow-up. The risk of cancer in the residual rectum has been reported to be 6 % at
20 years and 15 % at 30 years. The risk is significant considering that most patients are
young and have many years to live.
Farouk et al noted that in 1386 patients with restorative proctocolectomy and over 8-year
follow-up, 80% reported complete diurnal continence, with 50% requiring medications to
slow intestinal transit. [19]
4. Surgical options for Crohn's disease
Crohn's disease is not curable by surgery. Therefore, this is actualy reserved for complica‐
tions or to symptoms refractory to medical therapy [20].
Surgical decision making in Crohn's disease is driven by anatomic distribution and inflam‐
matory subtype of disease. Forty percent of patients have ileal disease with segments of co‐
lonic involvement, with 20–25% of patients exhibiting isolated colonic disease and 5–10%
with isolated anorectal disease [21]. Surgical intervention is primarily performed for the
complications of Crohn's disease: stricture and obstruction, fistula, or medically refractory
disease. Approximately 70% of Crohn's disease patients ultimately require surgery, often
multiple, making minimally invasive options appealing
Indications for surgery are:
• obstruction,
• perforation in small intestinal Crohn's disease,
• failure to respond to medical therapy in patients with colonic involvement,
• strictures,
• fistula
Surgery should to adress only to segments causing obstruction, bleeding, or perforation. Re‐
section is performed when there is an abscess or fistula to an adjacent organ. The disease-
free margins are established by gross inspection, microscopic disease at the margins will not
be associated with recurrence. Therefore we should avoid large margins, in the idea of pre‐
serving as much as possible of small bowel capital because the patients may need another
resection in the future and thus preventing the short bowel syndrome.
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Ileocolic resections should be followed by a side-to-side anastomosis. A meta-analysis of
eight comparative studies found that a side-to-side anastomosis was associated with fewer
anastomotic leaks and postoperative complications, a shorter hospital stay and a lower peri‐
anastomotic recurrence rates compared to end-to-end anastomosis [22]. However, the au‐
thors suggested that further randomized controlled trials are needed to confirm these
associations.
4.1. Duodenal disease
Duodenal Crohn's disease very rarely requires surgery. The major indications for surgery
are obstruction and less often perforation or fistula formation. Gastrojejunostomy rather
than resection is typically performed. Strictureplasty, duodenojejunostomy, and endoscopic
balloon dilation have also been described [23].
4.2. Intra-abdominal abscess, peritonitis
• Intraperitoneal abscesses were classically drain by open surgery and were followed by
surgical resection of the diseased segment of the bowel.
• Progress of interventional radiology, new biologic agents and progress of laparoscopy
changed this classic approach [24,25].
• Percutaneous drainage guided by CT or abdominal ultrasound has a low rate of compli‐
cations and a high rate of success - approximately 70% of attempted cases. Complete
drainage of the abscess may necessitate repeated punctures. This attitude allows the pa‐
tient to be prepared for an elective resection of the bowel after the sepsis resides, after im‐
proving nutritional status and decreasing corticosteroids. Controversy exists regarding
the need for subsequent operation after adequate abscess drainage as intractable disease
or recurrent abscess occurs in at least 30% of these patients within a year.
• If percutaneous drainage is unsuccessful, surgical drainage should be performed. The
timing of surgery following percutaneous abscess drainage, when clinically indicated, oc‐
curs after clinical resolution of sepsis.
• Peritonitis is rare in Crohn's disease. Exploratory laparotomy with peritoneal lavage, with
construction of a stoma is most commonly required. The decision whether to resect or not
the bowel depends upon the operative findings and the patient's condition [26].
• Abdominal wall abscesses (psoas and rectus sheath) are less common and more difficult to
control locally than intra-abdominal abscesses. In a retrospective review of 13 patients with
an abdominal wall abscess treated by percutaneous and/or open operative drainage, all 13
required resection of the diseased segment even after successful drainage of the abscess [25].
4.3. Fistulas
Fistulas to adjacent organs (stomach, duodenum, bladder, vagina, and sigmoid colon) are
treated by resection and anastomosis of the diseased segment of the bowel and closure of
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the fistula. Resection of the adjacent segment is necessary only when it is primarily involved
with Crohn's disease. Bypasses should be avoided because persistent disease in the by‐
passed segment can lead to abscess formation, bleeding, perforation, bacterial overgrowth,
and malignancy.
4.4. Strictures
Intestinal strictures can be relieved by resection; synchronous small bowel resection in pa‐
tients with multiple strictures is common [27]. Strictureplasty or balloon dilation may be a
suitable alternative for selected patients.
4.4.1. Strictureplasty
Strictureplasty is performed by longitudinal incision across the stricture and a transversal
closure that enlarges the lumen. Indication is represented by the patients that have isolated
areas of short stricture and are at risk for short bowel syndrome due to previous surgery or
extension of enterectomy. Strictureplasty can relieve obstruction, and is often performed in
association with a small bowel resection [27, 28]. It can also be performed without excision
of bowel [29, 30]. It should not be performed in acutely inflamed bowel.
To avoid large enterectomy for extensive and/or multiple strictures occurring over long in‐
testinal segments, a side-to-side isoperistaltic or other type of nonconventional strictureplas‐
ty is safe and effective [31, 32].
Strictureplasty has been associated with excellent results, including relief of obstruction, the
ability to withdraw steroids, and improvement in symptoms [31, 33] the risk of fistula or re‐
current stricture formation is low and comparable to resection. Whether preservation of dis‐
eased bowel increases the long-term risk of malignancy is unknown, although case reports
have documented adenocarcinoma arising from sites of previous strictureplasty [34].
The following examples illustrate the range of findings in two of the largest series
In a series of 1124 procedures of strictureplasty on 314 patients there was a synchronous
bowel resection in 66% of cases, overall morbidity was 18%, septic complications in 5%,
morbidity was higher in patients with preoperative weight loss and older age, recurrence af‐
ter surgery was met in 34% during a median follow-up of 7.5 years, recurrence was higher
in younger patients [30]:
Another study included 479 procedures of strictureplasty performed in 100 patients with a
follow-up of 7 years in average [35]. Overall morbidity was 22% and included sepsis – 11%,
obstruction 4%, hemorrhage - 4% percent, and mortality – 3%. After a first strictureplasty
the reoperation rate were 52% at 40 months, 56% at 26 months after a second, 86% at 27
months after a third, 63% at 26 months after a fourth. The major risk factor for reoperation
was young age. The early relaparotomy rate was 8 percent. One patient developed cancer
after many years of disease. The authors biopsied suspicious lesions, rather than going for
routine biopsy of all lesions.
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4.4.2. Balloon dilation
Another method to dilate intestinal strictures is with a hydrostatic balloon Experience is rel‐
atively limited compared with strictureplasty or resection, and the long-term efficacy and
safety is therefore less well-established. A meta-analysis of 13 studies (with a total of 347 pa‐
tients) reported overall technical success in 86 % of cases and long-term efficacy in 58 per‐
cent, with up to 33 months of follow-up [36]. On multivariate analysis, a stricture length of
≤4 cm was associated with better surgery-free outcomes. The outcome of balloon dilatation
to relieve obstruction from intestinal strictures in Crohn’s disease is not influenced by the
type of concomitant medical therapy [37].
Couckuyte et al performed 78 dilatation procedures for 59 ileocolonic strictures in 55 pa‐
tients, all procedures were carried out endoscopically under general anesthesia. Succes was
registered in 90% with 11% perforations from which 30% needed surgery and 60% were
solved only with medical treatment. Mean period of time to recurrence of obstruction was
up to 11 months for 62% of patients. [38]
In pediatric patients injections of corticosteroids into strictures after balloon dilatations were
followed by fewer redilatations than in placebo group. [39]. For adults it didn’t work the
same [40]
4.4.3. Stenting
Placement of an expandable metal stent within colonic strictures has been described, but ex‐
perience is limited, and the safety of this approach is uncertain [41].
4.5. Colorectal disease
Options for surgery range from temporary diverting ileostomy to resection of segments of
diseased colon or even the entire colon and rectum. Same conservative principles applied to
disease involving the small intestine should also be applied to the surgical management of
Crohn's colitis
The optimal procedure depends in part upon the extent of the disease and the clinical setting:
• Segmental colectomy may be adequate for isolated areas of colonic involvement. An Ileor‐
ectal anastomosis can be carried out if the rectum is spared. A proctectomy will be re‐
quired in half of the patients [42]. While no prospective randomized study has been
undertaken to compare segmental colectomy and total colectomy with ileorectal anasto‐
mosis, both procedures appear to be equally effective as treatment options for colonic
Crohn's disease. However, patients undergoing segmental resection may have earlier re‐
currence [43]. The choice of operation depends upon the extent of colonic disease; there
may be better outcomes with ileorectal anastomosis in those who have two or more in‐
volved colonic segments.
• Total proctocolectomy is indicated for patients with extensive, diffuse colorectal disease.
• Subtotal colectomy with ileostomy is usually performed in emergency situations.
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• An abdominoperineal resection with a permanent end-colostomy is indicated in patients
with severe Crohn's disease limited to the anorectum. An intersphincteric proctectomy
will minimize the risk of a nonhealing wound and sexual or urinary dysfunction, by
avoiding dissection near the hipogastric plexuses. In the presence of anorectal disease and
sepsis a Hartmann procedure can be carried out in the first place leaving a small stump of
distal rectum, followed by a perineal proctectomy. [44].
4.6. Anorectal disease
The management of anorectal disease, present in 14–38% of patients, remains difficult de‐
spite advances in medical therapy. Perianal fistula or abscess is the initial presentation of
Crohn's disease in approximately 30% of cases and has been associated with increased extra‐
intestinal symptoms and steroid resistance, resulting in significant disability [8].
The number of Crohn's patients who require surgery has, however, decreased with the ad‐
vances in medical management.
Most of the abscesses are small, difficult to drain and can disappear with antibiotics alone.
The antibiotic therapy should associate ciprofloxacin to metronidazole. Greater abscesses
can be drained by placement of a seton or by ultrasound or CT guided large bore needle as‐
piration or drain placement.
Treatment of the perianal fistula depends on the type of fistula (simple vs. complex) and un‐
derlying rectal inflammation.
Simple fistulas are intersphincteric or transsphincteric below the dentate line in origin with a
single opening and no associated stricture or abscess. Such fistulas have an excellent response
to antibiotic and surgical therapy and heal 80–100% of the time with simple fistulotomy [8]
Complex fistulas on the contrary, involve the superficial, transsphincteric, or intersphincter‐
ic region below the dentate line, have multiple openings, and can be associated with rectal
stricture or rectovaginal fistula.
Pelvic MRI provides the most accurate information (90% accuracy) about fistulous burden
and underlying rectal inflammation and is instrumental in surgical planning and monitor‐
ing response to therapy. Accuracy approaches 100% when MRI is combined with examina‐
tion under anesthesia. [45, 46]
Complex fistulas represent a challenge and require aggressive immunomodulating therapy
in combination with surgical therapy. Many patients feel improvement in symptoms with
antibiotic therapy (ciprofloxacin and metronidazole); however, symptom relief is transient
with recurrence on withdrawal of antibiotics. Infliximab has proven to be the immunosup‐
pressive drug of choice in treatment of complex perianal fistulas with two randomized trials
showing decreased number of fistulas, increased disease-free period, and fewer required
hospitalizations and surgeries.[47]
Surgical therapy has evolved for complex fistulas as well with the development of less inva‐
sive techniques for closure of high fistulas to prevent incontinence associated with damage
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to the anal sphincters. Some of the newest approaches use fibrin glue and collagen plugs to
occlude fistulous tracts without requiring incision.
A study from Chung et al comparing collagen fistula plug to fibrin glue, rectal advancement
flap, and seton placement for treatment of 51 patients with complex perianal fistulas showed
a 75% resolution rate with use of the plug compared with less than 30% for each of the other
modalities. [48]
The systematic review by Soltani and Kaiserof evaluating the efficacy of endorectal flap ad‐
vancement for complex perianal Crohn's disease found a 46% resolution [49].
The review by Lewis and Maron on anorectal Crohn's disease provides an algorithm for
management of complex perianal fistulas, stressing that surgical therapy in excess of seton
placement should not be attempted during active proctitis due to inflammation [50].
Postoperative medical treatment for prevention of Crohn's disease recurrence is controver‐
sial in light of data supporting increased incidence of complications with preoperative im‐
munosuppressive therapy. However, a randomized, placebo-controlled clinical trial showed
no difference in incidence of adverse events (anastomotic leak, wound complications, infec‐
tion, obstruction, bleeding, death) between postoperative patients treated with infliximab
within 4 weeks of surgery and those untreated. [51]
Bordeianou et al studied the effect of immediate vs. tailored medical prophylaxis on endo‐
scopic and/or symptomatic recurrence in 199 patients who underwent ileocecectomy for
Crohn's disease. The group found that there was no difference in recurrence rates between
patients treated with medication immediately after surgery and those treated based on en‐
doscopic finding, adding to the debate on whether perioperative and postoperative medical
suppression is advantageous. [52]
5. Minimally invasive surgery for inflammatory bowel disease
The laparoscopic approach was already proven feasible both for UC and CD.
5.1. Minimally invasive surgery for chronic ulcerative colitis
A way to use laparoscopy is only for the mobilization of the colon (cecum, ascendent, de‐
scendent, sigmoid) and to perform the rest of the operation in open but with a smaller inci‐
sion [53]
Laparoscopic subtotal colectomy performed in emergency conditions was followed by ac‐
ceptable outcomes and shorter hospital stay, although in such cases is not usually recom‐
mended [54].
Another possibility is to perform colon and rectal mobilisation, section of the mesocolon and
even the rectum with liniar ENDO-GIA. Some authors do that by hand assisted technique.
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5.1.1. To divert or not after laparoscopic surgery
This is a question still under debate. Ky et al had a series of 32 laparoscopic IPAA (29 for
UC) in which they didn’t divert and had a morbidity of 34% and 3% leak rate [55]. Hasega‐
wa et al performed 18 cases all with diversions and had 33% morbidity and 0% leak rate
[56]. Others like Marcello et al from 20 cases (13 for UC) divert only in 60% of cases and had
5% leak rate.[57]
Is laparoscopy superior to open approach? In short term yes – as already proven by compar‐
ison between them, with faster recovery (including faster ambulation, less postoperative
pain, faster return of bowel movement and time to first passage of flatus and feces).
Brown et al compared laparoscopic-assisted restorative proctocolectomy to open approach
and found shorter operative time in open group, and similar functional outcome and recov‐
ery, only better cosmesis by shorter abdominal scar. The hand-assisted method seems to re‐
duce the operative time with more than 30 minutes [58].
Postoperative morbidity is still relatively high duet o extensive procedure (25-34%) [55, 56, 57]
5.2. Minimally invasive surgery for Crohn’s disease
Laparoscopic approach have the potential of decreasing morbidity, speeding recovery, and
reducing costs, while decreasing the incidence of small bowel obstruction and ventral (ab‐
dominal wall) hernias [59,60].
A randomized comparative trial between open and laparoscopic ileo-colic resection found a
conversion rate of 6% and no significant difference in immediate postoperative recovery
(passage of flatus and length of hospital stay). The only benefice was a faster recovery of
forced expiratory volume and forced expiratory vital capacity. [61]
Maartense et al performed a comparative randomized controlled trial between laparoscopic-
assisted ileocolonic resection performed by experienced surgeons in laparoscopy with open
resections in Crohn's disease [62]. Morbidity, hospital stay, and costs were lower in the lapa‐
roscopic group, although there were no significant differences in quality-of-life at three
months follow-up.
Alves et al found that the need for conversion to an open procedure was predicted by the
severity of disease; independent predictors of conversion including a history of recurrent
medical episodes of Crohn's disease and the presence of intra-abdominal abscess or fistula at
the time of laparoscopy [63].
Recurrences after laparoscopic surgery were similar after conventional surgery. Laparoscop‐
ic colectomy was found to be safe and effective in the hands of experienced surgeons for se‐
lected patients with Crohn’s colitis [64].
In the review by Fichera et al on Crohn's disease, the author highlights three meta-analyses
that compared laparoscopic with open ileocolic surgery that demonstrated earlier return of
bowel function leading to shorter hospital stay, fewer late small bowel obstructions, and de‐
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creased early complications such as wound infections and bleeding with laparoscopic sur‐
gery. [20]
Two large studies on laparoscopic surgery for isolated colonic disease found similarly good
outcomes with fewer complications. Holubar et al reported their outcomes for 92 patients
who underwent laparoscopic colectomy, showing a total complication rate of 34%, reinter‐
vention rate of 7.6%, and anastomotic leak rate of 3.8%, all consistent with reported out‐
comes for open colectomy. Fifteen percent of laparoscopic cases were converted to open and
presence of small bowel disease was the only predictive factor identified, independent of
presence of phlegmonous or fistulous disease. [65]
Umanskiy et al compared outcomes of 125 patients who underwent laparoscopic vs. open co‐
lectomy and/or proctectomy for Crohn's disease. The most common procedure in both groups
was total proctocolectomy with end ileostomy and the only statistically significant difference
in procedures performed applied to completion proctectomies, which were more likely to be
open. Patients in the laparoscopic group had earlier return of bowel function, reduced length
of hospital stay, and decreased intraoperative blood loss. Interestingly, the reduced blood loss
did not result in fewer transfusions, which were similar in both groups [66].
5.2.1. Recurrence after laparoscopic surgery
There was also no clinical recurrence at 20 months [60]. In a study by Tabet et al with 39
months follow up, there were similar rates of recurrence 48% vs 45%. [67]
Watanabe et al and Bemelman et al performed laparoscopic-assisted resection for Crohn’s
disease, including patients with enteric fistulas. Postoperative outcome was better in laparo‐
scopic group [68, 69]. Same results were noted by Duepree et al., Tabet et al, and Young Fa‐
dok et al. (all comparative studies) who found short term outcome benefits associated with
the minimally invasive approach [60, 67, 70].
5.2.2. Costs
For Duepree et al costs per case were higher for laparoscopic group.[70]. Young-Fadok et al
reported an overall cost for laparoscopic cases significantly less than for the open ones [60].
There is a broad range of conversion rates (1.4-24 %), morbidity (10-29 %), length of stay
(3.3-8.8 days), and leak rates (0-5%). Most of the series involve relatively small numbers of
patients. [59, 69, 70]
5.2.3. Long term benefits of laparoscopic approach
Laparoscopic surgery is considered to generate less postoperative adhesions and less inci‐
sional hernias.
Bergamaschi et al reported the results of a comparative study with long term follow up be‐
tween laparoscopic and open ileocecal resections. At 5 years, they found a rate of 11.1 %
small bowel obstructions for laparoscopic group and 35.4 percent for the open group, and
the result was statistically significant.[59]
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Generally, laparoscopic colectomy is followed by lower incidence of incisional hernia and
small bowel obstruction, with significant differences, as reported by Duepree et al [70].
Functional outcome [71], quality of life [71] are similar but cosmetic results [71] especially
for women [72] are higher after laparoscopy.
6. Complications
6.1. Early complications
Are usual after restorative proctocolectomy.
The most frequent are bowel obstruction, pouch bleeding, pelvic and wound sepsis, transi‐
ent urinary dysfunction, and dehydration from temporary loop ileostomy with high output.
Surgery is not mandatory in many of those cases. Incidence of pelvic abscess after IPAA is
estimated to 5% [73]. Pelvic abscesses lead to transabdominal or local surgery in most of the
cases, failure of pouch in quarter of cases, incontinence, need for constipating or bulking
medications was in the patients in whom the reservoir was preserved. There was also a de‐
crease in the quality of life of those patients.
Portal vein thrombosis can occur after IPAA. Clinical manifestations may include pain, fe‐
ver, vomiting, leukocytosis, and unexplained postoperative ileus. Diagnose is made with
CT-scanner. Treatment with anticoagulation will lead to full resolution.
6.2. Late complications
• stricture of the anastomosis,
• poor postoperative anorectal function,
• anal fistula and abscess,
• reduced fertility [74],
• pouchitis - this is the most frequent. In one series, the cumulative probability of suffering at
least one episode of clinical pouchitis was 18 and 48 % at 1 and 10 years, respectively [75],
• irritable pouch syndrome and anismus (anorectal dysfunction)[76].
Majority of the pouch related complication can be solved by medical treatment consisting main‐
ly in local measures, surgery being required in a minority. In one series of almost 1000 patients
who had undergone IPAA, reoperation for complications was necessary in only 12 % [77].
As an example, ileal pouch fistulas and strictures refractory to dilatation are difficult to treat
and may require revision of the pouch if Crohn's disease can be excluded. A transvaginal
repair is favored for a pouch-vaginal fistula [78]. A combined abdominal perineal repair
may offer better results compared with a local procedure [79]. A controlled septic condition
does not preclude salvage surgery. Although pouch failure occurs more often than with pri‐
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mary IPAA, high patient satisfaction and quality of life can be achieved [80]. Furthermore,
excision of the pouch is associated with a high risk of complications, especially delayed peri‐
neal wound healing [81, 82].
A number of unusual late complications have been described including [83, 84, 85]:
• Solitary ileal ulcer
• Traumatic ileal ulcer perforation
• Superior mesenteric artery syndrome
• Mucosal prolapse with outlet obstruction
• Volvulus
• Sacral osteomyelitis
• Puborectal spasm
• Fibroid polyps
• Pharmacobezoar
6.3. Long-term results of surgery
The long-term success of surgery depends upon the type of operation, the clinical setting,
and surgical expertise. Several studies have suggested that functional results are poor dur‐
ing the long-term follow-up in patients who had adverse personality factors before surgery
(such as problems with sexual satisfaction, difficulty expressing emotions, perfectionist
body ideals, and poor frustration tolerance) [79]. The following results were described in
some of the largest series.
One series included 1885 patients who underwent an ileal pouch-anal anastomosis for ulcer‐
ative colitis and were followed for an average of 11 years. The mean number of stools was
5.7 per day at one year and 6.4 at 20 years, and also increased at night from 1.5 to 2.0. The
incidence of frequent fecal incontinence increased from 5 to 11 percent during the day and
from 12 to 21 percent at night. The overall rate of pouch success at 5, 10, 15, and 20 years
was 96, 93, 92, and 92 percent, respectively. Quality of life remained unchanged and 92 per‐
cent remained in the same employment. [86]
In another report that included 486 patients who had undergone proctocolectomy and ileoa‐
nal anastomosis for ulcerative colitis or familial adenomatous polyposis, the cumulative
probabilities of pouch failure were 1, 5, and 7 percent at 1, 5, and 10 years, respectively [87]
The most common cause of pouch failure was fistula formation.
Tulchinsky et al reported 634 patients who underwent restorative proctocolectomy for IBD.
Patients were followed for a mean of 85 months. Failure (defined as removal of the pouch or
the need for an ileostomy) was divided into early (occurring within one-year) or late (occur‐
ring more than one-year postoperatively). Three patients died postoperatively while an ad‐
ditional 23 died (of a variety of causes) during follow-up. Of the remaining patients, there
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were a total of 61 failures (10 %) of which 24.6% were early and 75.4% late. Failures were
due to pelvic sepsis (52 %), poor function (30 %), pouchitis (11 %), and miscellaneous causes
(four patients, all early failures). Predictors of failure included a final diagnosis of Crohn's
disease, a type J or S reservoir, female gender, postoperative pelvic sepsis, and a one-stage
procedure. Failure rates increased with time from 9% at five years to 13% at 10 years. [88]
Another series showed that results in older patients (>65) are not as good; however, appro‐
priate case selection was followed by acceptable function and quality of life to patients of all
ages [89].
Anal canal strictures were described in up to 11 percent of 213 patients [82]. Strictures that
were not fibrotic responded well after anal dilation while fibrotic strictures were more com‐
monly associated with intra- or postoperative complications and frequently required surgi‐
cal therapy.
A systematic review of 43 observational studies (with a total of 9317 patients) found a pouch
failure rate of 6.8%, increasing to 8.5% in those with more than five-year follow-up [90]. Pel‐
vic sepsis occurred in 9.5%. Severe, mild, and urge fecal incontinence was reported in 3.7, 17,
and 7.3 percent, respectively. These results suggest that current techniques are associated
with non-negligible complication rates and leave room for improvement and continued de‐
velopment of alternative procedures.
IPAA may have long-term effects:
• on female reproductive health [91],
• some women experience increased dyspareunia [92], although the ability to experience
orgasm and coital frequency remain unchanged,
• female fertility is significantly decreased [93], possibly due to pelvic adhesions, although
successful pregnancies occur regularly [94], patients may experience a transient increase
in stool frequency (including incontinence) during pregnancy, which resolves after deliv‐
ery, pregnancy and delivery are safe in patients with IPAA. Patients should not be dis‐
couraged from childbearing because of the pouch. Whether vaginal or cesarean delivery
is better for women with a pelvic pouch remains controversial.
Satisfactory long-term functional outcome and excellent quality of life have also been descri‐
bed after stapled restorative proctocolectomy. In a series of 977 patients, quality of life in‐
creased for two years after surgery, with no deterioration thereafter [95]. The prevalence of
perfect continence increased from 76 percent before surgery to 82 percent after surgery and,
although continence deteriorated somewhat more than two years after surgery, it was no
worse than preoperative values. Ninety-eight percent of patients would have recommended
the surgery to others. In another prospective, observational study, patients who had a sta‐
pled anastomosis had higher rates of daytime, nighttime, and complete continence com‐
pared with patients who underwent a hand-sewn anastomosis [32].
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6.4. Morbidity of operation due to use of biologic agents
Preoperative use of infliximab. The efficacy of the biologic agents must be balanced against the
morbidity associated with their usage, and surgeons have been worried about the safety as‐
sociated with the preoperative use of these medications in patients requiring elective or non‐
elective operations for their IBD.
Beddy et al believed the evidence showed that recent biologic agent administration in a pa‐
tient with Crohn's disease should not cause the surgeon to delay surgery or employ fecal di‐
version proximal to an anastomosis. However, they felt that patients with ulcerative colitis
preoperatively managed with infliximab and immunosuppressant medications should un‐
dergo a three-stage rather than two-stage restorative proctocolectomy and ileal pouch-anal
anastomosis (IPAA); the first operation would be a total or subtotal colectomy and creation
of ileostomy that allows patients to be withdrawn from medications prior to performing the
IPAA procedure. They proposed this approach in hopes of improving long-term ileal pouch
function by decreasing the risk of short-term infectious complications attributed to combina‐
tion therapy.[83]
Gainsbury et al, remarked that there is an increased risk of septic complications associated
with preoperative infliximab and elective surgery for ulcerative colitis, growing evidence
appears to refute that notion. [99]
Whether immunosuppressive therapy increases the risk of postoperative complications is
still controversy. For some authors [98, 99, 100, 101] it may not be responsible but for others
[102, 103, 104] it is, increasing risk for sepsis, intraabdominal abscesses [102,104], and espe‐
cially when associated with other immunomodulators (ciclosporin) [103]. In this conceptual
area there is need for more controlled trials.
Ellis et al found that unlike surgical mortality for most disorders, the operative mortality as‐
sociated with colectomy for ulcerative colitis has increased in recent years despite centraliza‐
tion of care. This finding raises considerable concern that patients potentially are not
receiving prompt or appropriate surgical care because of alterations in medical therapy.
[105]
6.5. Pouchitis
Outside of the perioperative period, the most common late complication of ileal pouch anal
anastomosis is pouchitis, occurring in up to 60% of patients.[106] Pouchitis is thought to be
the result of immunologic reaction to altered bowel flora. Symptoms range from mild diar‐
rhea to severe abdominal pain and fistulization with neighboring organs. In a recent review
from the Cleveland Clinic, multivariate analysis identified pulmonary co-morbidities, S-
pouch reconstruction, disease proximal to the splenic flexure, and extraintestinal disease are
the factors predictive of subsequent pouchitis. Patients who developed pouchitis had higher
incidence of obstruction, fistula, and stricture and reported lower quality of life than con‐
trols [94]. Once identified, the treatment of pouchitis is primarily medical, with most pa‐
tients showing excellent response to antibiotics and/or probiotics and immunomodulators.
A Cochrane database review of trials through 2010 found that ciprofloxacin was more effec‐
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tive than metronidazole and budesonide enemas were equally effective to metronidazole in
the treatment of acute pouchitis. The probiotic VSL#3 was more effective than placebo for
prevention and treatment of chronic pouchitis[108]. Haveranet al reported complete resolu‐
tion of symptoms in stricturing and antibiotic resistant pouchitis with azathioprine and 6-
mercaptorpurine. However, fistulizing disease required the addition of infliximab, with 46%
of such patients ultimately requiring diverting ileostomy for relief. Alternatives to ileostomy
for pouch failure include pouch salvage techniques such as transanal mobilization or ab‐
dominoperineal revision of the pouch, with success rates ranging from 48 to 93%.[18] A
small percentage of patients will ultimately be identified as having Crohn's disease as the
cause of their fistulae and pouch complications.[109]
In a review of almost 1800 IPAA attempts from the Mayo Clinic, abandonment was required
in 4.1 % [97].
7. Postoperative monitoring
Risk of dysplasia and cancer
All patients who undergo surgical procedures for ulcerative colitis should be monitored reg‐
ularly for the development of long-term complications.
In addition to functional problems, complications can occur at any stage, including the de‐
velopment of dysplasia and possibly cancer.
However, in a study of potentially high-risk patients (eg, Kock pouch for ≥14 years, a pelvic
pouch for ≥12 years, a history of dysplasia or cancer in the proctocolectomy specimen or
troublesome pouchitis), the development of dysplasia was rare [98].
7.1. Dysplasia
The presence of inflammatory changes in a retained rectal stump, anal transitional zone, and
ileal reservoir after stapled pouch-anal anastomosis is a cause of concern because of the
long-term risk of dysplasia.
A systematic review of 23 observational and case control studies estimated that the preva‐
lence of confirmed dysplasia in the pouch, anal transitional zone, or rectal cuff was 1.13 %
(0-19%) The prevalence of high-grade, low-grade, or indefinite dysplasia was 0.15, 0.98, and
1.23 %, respectively. Dysplasia was equally frequent in the pouch and rectal cuff or anal
transitional zone [112].
If dysplasia and cancer are identified before or at operation the risk for postoperative dys‐
plasia is higher. The risk of neoplasia is not completely eliminated by colectomy and muco‐
sectomy. A retrospective review of 3203 patients with a preoperative diagnosis of IBD who
underwent restorative proctocolectomy found that the cumulative incidence for pouch neo‐
plasia at 5, 10, 15, 20 and 25 years were 0.9, 1.3, 1.9, 4.2, and 5.1 %, respectively 11 patients
developed adenocarcinoma of the pouch or at the anal transitional zone, one developed
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lymphoma in the pouch, three developed squamous cell carcinoma at the anal transitional
zone, and 23 developed pouch dysplasia. The prognosis of pouch adenocarcinoma appeared
to be poor [100].
If the rectal cuff becomes symptomatic or develops dysplasia, the retained rectal mucosa
from the restorative proctocolectomy can be removed by a transanal completion mucosecto‐
my and reconstructing the ileal pouch-anal anastomosis as an alternative to a complete anal
rectal resection and permanent ileostomy. The mucosectomy removes all rectal mucosa, con‐
fers a highest likelihood of a surgical cure, and reduces the risk of future dysplasia. Short
term results in a series of 27 patients included reduced pouchitis symptoms and 90 % of pa‐
tients were moderately to very satisfy with the procedure. Incontinence was reduced by 70
percent at 12 months of observation [101].
The optimal frequency of pouch endoscopy and biopsy is not well established. It is recom‐
mended to perform an initial screening five years after creation of an ileal pouch in children
or when the total disease duration exceeds seven years [102].
In patients that had severe villous atrophy or dysplasia in the resected colon or rectum the
aforementioned interval may be reduced. In patients with pouch or anal high-grade dyspla‐
sia detected during surveillance, resection of the ileal pouch and anal canal should be con‐
sidered.
In a retrospective review of 222 patients who required operative intervention for Crohn's
colitis, there were 2.3% dysplasia and 2.7% adenocarcinoma. In this small cohort, the risk
factors for the development of dysplasia or adenocarcinoma included longer disease dura‐
tion (over 17 years), extensive disease, and older age at diagnosis (38 years of age or older).
These findings support colonoscopic screening and surveillance of patients with Crohn's
colitis. [116]
7.2. Recurrence
The postoperative recurrence rate for patients undergoing a resection and anastomosis is
high in Crohn’s disease. In most series up to 20 percent of patients will not have a clinical
recurrence even at 15 years after surgery Those with severe endoscopic or radiologic find‐
ings are at increased risk to have or develop symptoms (72 versus 42%). An increased risk
for reoperation has been associated with perforating disease and smoking [117].
A laparoscopic approach does not appear to decrease the risk of recurrence. A retrospective
review of 89 patients undergoing laparoscopically resected primary ileocolonic Crohn’s coli‐
tis found recurrent disease in 61 percent [118]. The median time to recurrence was 13
months (range 1.3 months to 8.7 years). Only the presence of granulomas in the resected
specimen was identified as a risk factor for time to recurrence, and these patients were al‐
most three times more likely to develop a recurrence.
The recurrence rate is lower in patients with Crohn's colitis who undergo a total colectomy
and ileostomy compared to those with disease involving other segments of the digestive
tract. We already know, from a study in 1985 by Goligher et al Such patients have only a 10
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percent recurrence rate in the small intestine at 10 years [106]. A number of medical options
are available that may reduce the risk of recurrence. A relatively aggressive approach
should be considered in patients with diffuse and distal Crohn's colitis. Total proctocolecto‐
my in properly selected patients is associated with low morbidity, a decreased risk of recur‐
rence, and a longer time to recurrence [20]
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